3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
3
Breast
3
Head & Neck
2
Dermatologic
2
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Conditions
Sarcoma
10
Sarcoma, Alveolar Soft Part
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Melanoma
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Vulvar Neoplasms
1
Urogenital Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Obesity
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Interventions
Surveys and Questionnaires
3
Sunitinib
3
Radiosurgery
2
Observation
2
IDRX-42
2
trastuzumab deruxtecan
1
repotrectinib
1
ponatinib
1
pazopanib
1
nilotinib
1
montanide ISA 51
1
atezolizumab
1
amminedichloro(2-methylpyridine)platinum(II)
1
alectinib
1
Transurethral Resection of Prostate
1
Sildenafil Citrate
1
Radiotherapy
1
Quality of Life
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Oncolytic Virotherapy
1
Microscopy, Electron
1
Interleukin-2
1
Injections
1
Imatinib Mesylate
1
Drug Therapy
1
Doxorubicin
1
Cytoreduction Surgical Procedures
1
Cryosurgery
1
Cisplatin
1
CYT-6091
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
atezolizumab
×
Sarcoma
×
Clear all
NCT04273061
2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2
Recruiting
200 enrolled